As GLP-1 medications such as Ozempic and Wegovy affect the weight management category, a new consumer insight study from raw material supplier Chemi Nutra (Austin, TX) reveals an underreported risk from GLP-1 usage—muscle loss—and a strong demand for supplement solutions.
According to the report, GLP-1 users are the most likely group to want muscle-protecting supplements during weight loss with 78 percent “definitely” or “very interested.”
Among current users, 64 percent are aware of the risks of muscle loss, but less than half (46 percent) of non-users are aware, highlighting a significant education gap in the market. Interest in muscle protection remains high after GLP-1 discontinuation with 71 percent pointing to a lasting need for ongoing nutritional support, the report said.
Nearly half of all current users (47 percent) reported emotional or mental side effects related to “rapid physical transformation,” reinforcing the needs for solutions that support the body and mind, the report said.
“GLP-1s are powerful tools, but they can leave a gap between the body people are living in and how they feel in it. Muscle preservation isn’t just a physical benefit: it’s part of helping people stay confident, capable, and connected to themselves through change,” said Michael Petteruti, president of Chemi Nutra.
For more information, visit www.cheminutra.com.
